



Participant Flow


Angiosarcoma Group




Leiomyosarcoma Group



Synovial Sarcoma Group



Other Sarcoma Group



Baseline patients characteristics

Table 1: Number of patients within each sarcoma subgroup

Sarcoma Type (N (%))	
Angiosarcoma	39 (27)
Leiomyosarcoma	36 (25)
Synovial Sarcoma	36 (25)
Other	34 (23)
Total	145 (100)

Table 2: Details of the histologies of patients recruited to the Angiosarcoma, Leiomyosarcoma, Synovial & Other Sarcoma cohorts as reported on the baseline form. Histology information was not available for all patients on the baseline form, for those who information was available disease subgroup has been reported.

Sarcoma group	Sub- Histology	N	%
Angiosarcoma	Haemangioendothelioma	1	3
	Haemangioendothelioma Of Liver	1	3
	Hemangiosarcoma	1	3
	Angiosarcoma Left Breast	1	3
	Kaposi'S Sarcoma	1	3
	Epithelioid Hemangioendothelioma	2	5
	Epithelioid Angiosarcoma	2	5
	Angiosarcoma	30	77
Leiomyosarcoma	Metastatic Uterine Leiomyosarcoma	1	3
	Metastatic Uterine Leiomyosarcoma/Myofibrosarcoma	1	3
	Pleomorphic Leiomyosarcoma	1	3
	Malignant Uterine Pecoma	1	3
	Grade 2 Retroperitoneal Leiomyosarcoma	1	3
	Grade 2	1	3
	Leiomyosarcoma	30	83
Synovial Sarcoma	Monophasial Synovial Sarcoma	1	3
	Left Pelvic Wall Synovial Sarcoma	1	3
	Spindle Cell Small Bowel	1	3
	Synovial Sarcoma	33	92
Other	Cystosarcoma Phyllodes	1	3
	Pleomorphic Undifferentiated Sarcoma	1	3
	Solitary Fibrous Tumour With Multiple Lung Mets	1	3
	Spindle Cell Sarcoma Nos	1	3
	High Grade Spindle Cell Sarcoma	1	3
	Epithelioid Sclerosing Fibrosarcoma	1	3
	Metastatic Spindle Cell Sarcoma	1	3
	Neurofibrosarcoma	1	3
	Myxoid Sarcoma	1	3
	Fibrosarcoma	1	3
	Metastatic Pleomorphic Sarcoma	1	3
	Poorly Differentiated Uterine Sarcoma	1	3
	High Grade Pleomorphic Sarcoma Showing Myofibroblastic Differenti- ation	1	3
	High Grade Endometrial Stromal Sarcoma	1	3
	Fibrous Tumour	1	3
	Spindle Cell Sarcoma	1	3

Soft Tissue And Solitary Fibrous Tumour	1	3
High Grade Pleomorphic Soft Tissue Sarcoma	1	3
Desmoplastic Small Round Cell Tumor	1	3
Pleomorphic Sarcoma	2	6
Myxoid Liposarcoma	2	6
Solitary Fibrous Tumour	3	9
Liposarcoma	4	12
Alveolar Soft Part Sarcoma	4	12

Table 3. Baseline patient demographics, split by Sarcoma type

	Angiosarcoma (39)	Leiomyosarcoma (36)	Synovial Sarcoma (36)	Other (34)	Overall (145)
Sex (N (%))					
Male	14 (36)	10 (28)	18 (50)	21 (62)	63 (43)
Female	25 (64)	26 (72)	18 (50)	13 (38)	82 (57)
Total	39 (100)	36 (100)	36 (100)	34 (100)	145 (100)
Age					
N	39	36	36	34	145
Mean (sd)	61 (15)	57 (11)	45 (16)	51 (15)	54 (16)
Median	64	59	44	50	56
IQR	55, 72	51, 63	32, 59	38, 65	42, 65
Range	27, 82	29, 79	20, 73	21, 80	20, 82
Age (N (%))					
18-64	21 (54)	29 (81)	31 (86)	25 (74)	106 (73)
≥65	18 (46)	7 (19)	5 (14)	9 (26)	39 (27)
Total	39 (100)	36 (100)	36 (100)	34 (100)	145 (100)

Table 4. Baseline disease and tumour details, split by Sarcoma type

	Angiosarcoma (39)	Leiomyosarcoma (36)	Synovial Sarcoma (36)	Other (34)	Overall (145)
Primary Tumour Location (N (%))					
Liver	2 (5)	1 (3)	0 (0)	1 (3)	4 (3)
Lymph	1 (3)	0 (0)	0 (0)	0 (0)	1 (1)
Lung	2 (5)	0 (0)	4 (11)	4 (12)	10 (7)
Bone	1 (3)	0 (0)	0 (0)	2 (6)	3 (2)
Other soft tissue	1 (3)	1 (3)	1 (3)	0 (0)	3 (2)
Upper limb	1 (3)	1 (3)	2 (6)	1 (3)	5 (3)
Lower limb	5 (13)	9 (25)	16 (44)	9 (26)	39 (27)
Shoulder girdle	0 (0)	0 (0)	2 (6)	1 (3)	3 (2)
Pelvic girdle	0 (0)	2 (6)	1 (3)	5 (15)	8 (6)
Breast	9 (23)	0 (0)	0 (0)	1 (3)	10 (7)
Head & Neck	7 (18)	0 (0)	1 (3)	0 (0)	8 (6)
Other intraabdominal	2 (5)	8 (22)	5 (14)	4 (12)	19 (13)
Other trunk	4 (10)	0 (0)	3 (8)	3 (9)	10 (7)
Uterus	0 (0)	12 (33)	0 (0)	2 (6)	14 (10)
Other	4 (10)	2 (6)	1 (3)	1 (3)	8 (6)
Total	39 (100)	36 (100)	36 (100)	34 (100)	145 (100)
Trojani Grade (N (%))					
1	3 (8)	2 (6)	0 (0)	2 (6)	7 (5)
2	9 (23)	12 (33)	11 (31)	7 (21)	39 (27)
3	20 (51)	16 (44)	20 (56)	16 (47)	72 (50)
Not supplied	0 (0)	0 (0)	0 (0)	1 (3)	1 (1)
Not known	7 (18)	6 (17)	5 (14)	8 (24)	26 (18)
Total	39 (100)	36 (100)	36 (100)	34 (100)	145 (100)
Time from first diagnosis to registration (years)					
N	39	36	36	34	145
Mean (sd)	2 (2)	2 (2)	3 (3)	4 (5)	3 (3)
Median	2	2	2	2	2
Range	0, 9	0, 11	0, 11	0, 22	0, 22

Table 5: Baseline physical assessments split by sarcoma type

	Angiosarcoma (39)	Leiomyosarcoma (36)	Synovial Sarcoma (36)	Other (34)	Overall (145)
Height (m)					
N	37	35	36	33	141
Mean (sd)	1.7 (0.1)	1.7 (0.1)	1.7 (0.1)	1.7 (0.1)	1.7 (0.1)
Range	1.5, 1.8	1.5, 1.9	1.5, 1.8	1.5, 1.9	1.5, 1.9
Weight (kg)					
N	39	36	36	34	145
Mean (sd)	79.8 (19.2)	73.4 (14.6)	76.3 (18.5)	79.3 (14.9)	77.2 (17.0)
Range	46.4, 127.0	44.3, 102.4	47.3, 124.0	52.2, 102.1	44.3, 127.0
Systolic Blood Pressure (mmHg)					
N	39	36	36	34	145
Mean (sd)	127.3 (17.8)	124.5 (12.6)	120.4 (16.9)	124.2 (13.6)	124.2 (15.5)
Range	96.0, 176.0	104.0, 154.0	80.0, 184.0	95.0, 148.0	80.0, 184.0
Diastolic Blood Pressure (mmHg)					
N	39	36	36	34	145
Mean (sd)	78.3 (11.9)	78.2 (6.0)	74.4 (11.2)	75.6 (9.0)	76.7 (9.9)
Range	55.0, 107.0	67.0, 88.0	58.0, 99.0	57.0, 90.0	55.0, 107.0
Pulse Rate (BPM)					
N	39	36	36	34	145
Mean (sd)	84.9 (15.0)	84.9 (16.2)	86.6 (14.5)	83.3 (16.2)	85.0 (15.3)
Range	52.0, 120.0	50.0, 116.0	59.0, 126.0	56.0, 127.0	50.0, 127.0
WHO Performance Status (N (%))					
0	18 (46.2)	10 (27.8)	16 (44.4)	7 (20.6)	51 (35.2)
1	18 (46.2)	22 (61.1)	18 (50.0)	25 (73.5)	83 (57.2)
2	3 (7.7)	3 (8.3)	2 (5.6)	2 (5.9)	10 (6.9)
Not known	0 (0.0)	1 (2.8)	0 (0.0)	0 (0.0)	1 (0.7)
Total	39 (100.0)	36 (100.0)	36 (100.0)	34 (100.0)	145 (100.0)

Urine Dipstick Result (N (%))					
Negative or 1+ greater or equal to 2+ Not known	36 (92.3) 0 (0.0) 3 (7.7)	33 (91.7) 0 (0.0) 3 (8.3)	34 (94.4) 0 (0.0) 2 (5.6)	27 (79.4) 1 (2.9) 6 (17.6)	130 (89.7) 1 (0.7) 14 (9.7)
Total	39 (100.0)	36 (100.0)	36 (100.0)	34 (100.0)	145 (100.0)

Table 6: Baseline biochemistry measures, split by Sarcoma type

	Angiosarcoma (39)	Leiomyosarcoma (36)	Synovial Sarcoma (36)	Other (34)	Overall (145)
Creatine Clearance (ml/min)					
N	39	35	35	34	143
Mean (sd)	99.6 (42.1)	93.7 (30.4)	106.8 (31.5)	115.2 (51.6)	103.7 (40.2)
Range	53.3, 222.1	52.5, 179.0	50.0, 178.0	55.0, 328.1	50.0, 328.1
Urea (mmol/L)					
N	39	36	36	34	145
Mean (sd)	5.2 (1.7)	4.7 (1.4)	4.4 (1.4)	5.0 (1.2)	4.8 (1.5)
Range	2.8, 13.0	1.9, 7.2	2.1, 8.7	2.7, 7.6	1.9, 13.0
Albumin (g/L)					
N	39	36	35	34	144
Mean (sd)	40.1 (5.1)	40.8 (5.3)	43.0 (5.6)	39.8 (5.4)	40.9 (5.4)
Range	29.0, 48.0	31.0, 50.0	27.0, 51.0	24.0, 49.0	24.0, 51.0
Total Protein (g/L)					
N	38	35	32	34	139
Mean (sd)	70.2 (4.6)	71.0 (5.1)	71.4 (7.6)	71.6 (5.7)	71.0 (5.8)
Range	63.0, 80.0	61.0, 80.0	49.0, 82.0	60.0, 83.0	49.0, 83.0
Bilirubin (umol/L)					
N	39	36	36	34	145
Mean (sd)	9.2 (5.0)	8.4 (3.1)	9.3 (4.3)	9.5 (3.5)	9.1 (4.1)
Range	2.0, 23.0	4.0, 14.0	5.0, 27.0	4.0, 19.0	2.0, 27.0
AST (IU/L)					
N	28	18	26	15	87
Mean (sd)	27.0 (13.7)	29.3 (11.8)	21.1 (4.0)	23.5 (8.8)	25.1 (10.7)
Range	15.0, 69.0	16.0, 66.0	11.0, 29.0	14.0, 47.0	11.0, 69.0
ALT (IU/L)					
N	35	27	29	21	112
Mean (sd)	20.5 (11.0)	25.2 (10.8)	20.8 (10.9)	26.4 (23.0)	22.8 (14.0)
Range	7.0, 45.0	8.0, 48.0	8.0, 52.0	9.0, 114.0	7.0, 114.0
Gamma-GT (IU/L)					
N	38	35	34	32	139
Mean (sd)	38.5 (29.9)	143.1 (237.1)	68.2 (88.6)	70.8 (97.9)	79.6 (140.2)
Range	10.0, 147.0	11.0, 1151.0	5.0, 397.0	11.0, 490.0	5.0, 1151.0
Alkaline Phosphatase (IU/L)					
N	39	36	36	34	145

Mean (sd)	91.6 (42.9)	167.2 (203.0)	100.2 (51.5)	143.6 (93.8)	124.7 (118.9)
Range	35.0, 215.0	42.0, 1191.0	35.0, 261.0	44.0, 386.0	35.0, 1191.0

Table 7: Baseline Haematology and Thyroid function measures, split by Sarcoma type

	Angiosarcoma (39)	Leiomyosarcoma (36)	Synovial Sarcoma (36)	Other (34)	Overall (145)
Haemoglobin (g/dL)					
N	39	36	36	34	145
Mean (sd)	13.0 (1.7)	12.4 (1.9)	12.9 (1.8)	12.1 (2.1)	12.6 (1.9)
Range	9.2, 17.2	7.9, 17.0	9.5, 16.2	7.4, 16.8	7.4, 17.2
White Blood Cell Count (×10⁹/L)					
N	39	36	36	34	145
Mean (sd)	8.1 (2.4)	7.8 (3.6)	7.2 (3.6)	6.9 (2.8)	7.5 (3.1)
Range	4.2, 13.4	3.0, 19.9	3.1, 21.4	3.2, 15.2	3.0, 21.4
Neutrophils (×10⁹/L)					
N	39	36	36	34	145
Mean (sd)	5.5 (2.2)	5.5 (3.2)	5.2 (3.2)	4.8 (2.4)	5.3 (2.8)
Range	2.8, 12.2	1.6, 18.2	1.7, 18.1	2.0, 12.1	1.6, 18.2
Platelets (×10⁹/L)					
N	39	36	36	34	145
Mean (sd)	293.4 (99.8)	310.7 (117.6)	292.4 (103.1)	284.1 (140.6)	295.2 (114.9)
Range	138.0, 631.0	152.0, 718.0	134.0, 599.0	145.0, 787.0	134.0, 787.0
INR					
N	38	36	33	31	138
Mean (sd)	1.0 (0.1)	1.0 (0.1)	1.1 (0.2)	1.0 (0.1)	1.0 (0.1)
Range	0.8, 1.3	0.9, 1.3	0.9, 1.7	0.9, 1.2	0.8, 1.7
TSH (mIU/L)					
N	37	36	35	34	142
Mean (sd)	2.4 (2.3)	2.0 (1.5)	2.5 (2.4)	2.1 (2.2)	2.2 (2.1)
Range	0.5, 11.4	0.4, 9.0	0.3, 14.1	0.1, 12.6	0.1, 14.1
FT4 (pmol/L)					
N	38	35	35	33	141
Mean (sd)	14.4 (3.5)	15.6 (2.7)	15.5 (2.9)	15.7 (2.4)	15.3 (2.9)
Range	1.7, 21.7	10.4, 24.9	10.8, 22.3	11.3, 25.0	1.7, 25.0

Table 8: Baseline Cardiac function measures, split by Sarcoma type

	Angiosarcoma (39)	Leiomyosarcoma (36)	Synovial Sarcoma (36)	Other (34)	Overall (145)
Chest X-ray performed (N (%))					
No	13 (33.3)	10 (27.8)	6 (16.7)	13 (38.2)	42 (29.0)
Yes	23 (59.0)	24 (66.7)	28 (77.8)	21 (61.8)	96 (66.2)
Not Supplied	3 (7.7)	2 (5.6)	2 (5.6)	0 (0.0)	7 (4.8)
Total	39 (100.0)	36 (100.0)	36 (100.0)	34 (100.0)	145 (100.0)
ECG performed (N (%))					
No	1 (2.6)	1 (2.8)	0 (0.0)	0 (0.0)	2 (1.4)
Yes	38 (97.4)	35 (97.2)	36 (100.0)	34 (100.0)	143 (98.6)
Total	39 (100.0)	36 (100.0)	36 (100.0)	34 (100.0)	145 (100.0)
ECG result (N (%))					
Normal	35 (89.7)	30 (83.3)	35 (97.2)	31 (91.2)	131 (90.3)
Abnormal	4 (10.3)	4 (11.1)	1 (2.8)	3 (8.8)	12 (8.3)
Not Applicable	0 (0.0)	2 (5.6)	0 (0.0)	0 (0.0)	2 (1.4)
Total	39 (100.0)	36 (100.0)	36 (100.0)	34 (100.0)	145 (100.0)
LVEF (%)					
N	36	35	35	33	139
Mean (sd)	62.6 (8.1)	63.2 (4.9)	61.3 (6.2)	61.1 (5.4)	62.1 (6.3)
Range	45.0, 80.0	54.0, 73.0	45.0, 72.0	50.0, 72.0	45.0, 80.0
ECHO performed (N (%))					
No	6 (15.4)	7 (19.4)	10 (27.8)	7 (20.6)	30 (20.7)
Yes	33 (84.6)	25 (69.4)	25 (69.4)	27 (79.4)	110 (75.9)
Not Specified	0 (0.0)	4 (11.1)	1 (2.8)	0 (0.0)	5 (3.4)
Total	39 (100.0)	36 (100.0)	36 (100.0)	34 (100.0)	145 (100.0)
MUGA performed (N (%))					
No	25 (64.1)	23 (63.9)	20 (55.6)	21 (61.8)	89 (61.4)
Yes	6 (15.4)	11 (30.6)	11 (30.6)	7 (20.6)	35 (24.1)
Not Specified	8 (20.5)	2 (5.6)	5 (13.9)	6 (17.6)	21 (14.5)
Total	39 (100.0)	36 (100.0)	36 (100.0)	34 (100.0)	145 (100.0)

Outcome Measures

Primary outcome

Table 9: Table of PFS rate, presented for all patients and split by Sarcoma subgroup

Sarcoma Group	Proportion	PFS Rate (95% LCI)
All Sarcomas	54/121	45% (37%)
Angiosarcoma	13/31	42% (29%)
Leiomyosarcoma	15/33	45% (32%)
Synovial Sarcoma	17/30	57% (42%)
Other Sarcoma	9/27	33% (21%)

Table 10: Patients status at 12 weeks

	Angiosarcoma (31)	Leiomyosarcoma (33)	Synovial Sarcoma (30)	Other (27)	Overall (121)
Status at 12 weeks (N (%))					
Alive and Progression Free	13 (42)	15 (45)	17 (57)	9 (33)	54 (45)
Death	2 (6)	1 (3)	4 (13)	2 (7)	9 (7)
Not Evaluable	3 (10)	1 (3)	1 (3)	1 (4)	6 (5)
Progressive Disease	13 (42)	16 (48)	8 (27)	15 (56)	52 (43)
Total	31 (100)	33 (100)	30 (100)	27 (100)	121 (100)

Secondary outcomes

Table 11: Table of response rate, as per RECIST criteria, presented for all patients and split by Sarcoma subgroup

Sarcoma Group	Proportion	Response Rate (95% CI)
All Sarcomas	6/121	5% (2, 10)
Angiosarcoma	2/31	6% (2, 21)
Leiomyosarcoma	0/33	0% (0, 10)
Synovial Sarcoma	3/30	10% (3, 26)
Other Sarcoma [†]	1/27	4% (1, 18)

[†] The sarcoma type for the patient in this group that responded was given to be Endometrial Stromal Sarcoma

Table 12: Table of Progression Free Survival outcomes, presented for all patients and split by Sarcoma subgroup

Sarcoma Group	Median PFS (months)	12 Month PFS Rate
All Sarcomas	2.9 (95%CI; 2.6, 3.8)	12% (95%CI; 7, 18)
Angiosarcoma	3.0 (95%CI; 2.4, 6.8)	19% (95%CI; 9, 34)
Leiomyosarcoma	2.8 (95%CI; 2.6, 5.1)	6% (95%CI; 1, 17)
Synovial Sarcoma	3.1 (95%CI; 2.2, 5.4)	12% (95%CI; 4, 25)
Other Sarcoma	2.8 (95%CI; 2.5, 3.8)	10% (95%CI; 2, 23)

Table 13: Table of Progression Free Interval outcomes, presented for all patients and split by Sarcoma subgroup

Sarcoma Group	Median PFI (months)	12 Month PFI Rate
All Sarcomas	2.9 (95%CI; 2.6, 3.8)	12% (95%CI; 7, 19)
Angiosarcoma	3.0 (95%CI; 2.4, 6.8)	22% (95%CI; 10, 36)
Leiomyosarcoma	2.8 (95%CI; 2.6, 5.1)	6% (95%CI; 1, 17)
Synovial Sarcoma	3.2 (95%CI; 2.4, 5.4)	12% (95%CI; 4, 26)
Other Sarcoma	2.8 (95%CI; 2.5, 3.8)	10% (95%CI; 2, 23)

Table 14: Table of Overall Survival outcomes, presented for all patients and split by Sarcoma subgroup

Sarcoma Group	Median OS (months)	12 Month OS Rate
All Sarcomas	9.9 (95%CI; 9.1, 12.0)	40% (95%CI; 32, 49)
Angiosarcoma	8.6 (95%CI; 5.3, 17.8)	40% (95%CI; 24, 56)
Leiomyosarcoma	11.4 (95%CI; 9.2, 12.6)	40% (95%CI; 24, 56)
Synovial Sarcoma	9.7 (95%CI; 7.5, 17.6)	47% (95%CI; 30, 63)
Other Sarcoma	9.9 (95%CI; 6.7, 14.1)	34% (95%CI; 18, 50)

Table 15: Change in performance score from baseline to Cycle 3, containing all patients

Baseline WHO Score	0 (48)	1 (78)	2 (9)	Not Known (1)	Overall (136)
Change					
Improvement (1 Point)	0 (0.0)	7 (9.0)	0 (0.0)	0 (0.0)	7 (5.1)
No Change	23 (47.9)	38 (48.7)	2 (22.2)	0 (0.0)	63 (46.3)
Worsened (1 Point)	12 (25.0)	7 (9.0)	0 (0.0)	0 (0.0)	19 (14.0)
Worsened (2 Points)	1 (2.1)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.7)
Not Known	12 (25.0)	26 (33.3)	7 (77.8)	1 (100.0)	46 (33.8)
Total	48 (100.0)	78 (100.0)	9 (100.0)	1 (100.0)	136 (100.0)

Table 16: Change in performance score from baseline to Cycle 3, containing only patients who had scores at both Baseline and Cycle 3

Baseline WHO Score	0 (36)	1 (52)	2 (2)	Overall (90)
Change				
Improvement (1 Point)	0 (0.0)	7 (13.5)	0 (0.0)	7 (7.8)
No Change	23 (63.9)	38 (73.1)	2 (100.0)	63 (70.0)
Worsened (1 Point)	12 (33.3)	7 (13.5)	0 (0.0)	19 (21.1)
Worsened (2 Points)	1 (2.8)	0 (0.0)	0 (0.0)	1 (1.1)
Total	36 (100.0)	52 (100.0)	2 (100.0)	90 (100.0)

Adverse Events

Angiosarcoma

Table 17: Number and percentage of patients experiencing an adverse event reported by the maximum grade experienced and split by CTCAE categorisations and toxicity in the Angiosarcoma subgroup

Category	Toxicity	Grade	Affected	Exposed	Percentage Affected
Musculoskeletal and connective tissue disorders	Arthralgia	1	8	36	22
		2	3	36	8
		3	1	36	3
	Back pain	1	3	36	8
		2	1	36	3
		3	1	36	3
	Bone pain	3	1	36	3
	Chest wall pain	1	1	36	3
		2	2	36	6
	Cramp	1	1	36	3
	Gout	2	1	36	3
	Joint range of motion decreased	2	1	36	3
	Myalgia	1	1	36	3
	Neck pain	3	1	36	3
	Pain in extremity	1	5	36	14
		2	2	36	6
		3	1	36	3
Nervous system disorders	Dizziness	1	4	36	11
	Dysgeusia	1	3	36	8
		2	1	36	3
	Dyskinesia	1	1	36	3
	Dysphasia	1	1	36	3

Psychiatric disorders	Headache	1	10	36	28
		2	2	36	6
	Paresthesia	1	1	36	3
	Peripheral sensory neuropathy	1	1	36	3
	Confusion	1	1	36	3
	Depression	1	2	36	6
	Insomnia	1	5	36	14
		2	1	36	3
Renal and urinary disorders	Dysuria	1	1	36	3
	Elevated urea	1	1	36	3
	Proteinuria	1	8	36	22
Reproductive system and breast disorders		2	1	36	3
	Menorrhagia	1	1	36	3

Category	Toxicity	Grade	Affected	Exposed	Percentage Affected
Respiratory, thoracic and mediastinal disorders	Bronchopulmonary hemorrhage	1	1	36	3
	Cough	1	10	36	28
		2	1	36	3
	Dysphonia	1	1	36	3
	Dyspnea	1	8	36	22
		2	8	36	22
		3	2	36	6
	Epistaxis	1	1	36	3
	Haemoptysis	2	1	36	3
	Hoarseness	1	2	36	6
	Pleural effusion	3	1	36	3
	Pleuritic pain	3	1	36	3
	Pneumothorax	2	1	36	3
	Rhinorrhea	1	1	36	3
	Voice alteration	1	14	36	39
		2	3	36	8
		3	1	36	3
Skin and subcutaneous tissue disorders	Alopecia	1	2	36	6
	Blister right foot	1	1	36	3
	Brittle nails	1	1	36	3
	Bullous dermatitis	3	1	36	3
	Dry skin	1	1	36	3
		2	2	36	6
	Dyschromia	1	1	36	3
	Nail discoloration	1	1	36	3
	Palmar-plantar erythrodysesthesia syndrome	1	4	36	11
		2	4	36	11
	Peeling scrotal skin	2	1	36	3
	Pruritus	2	2	36	6
	Rash acneiform	1	5	36	14
	Scalp pain	2	1	36	3
	Skin hypopigmentation	1	1	36	3
Vascular disorders	Flushing	1	1	36	3
	Haemorrhage	1	2	36	6
		2	3	36	8
	Hematoma	1	1	36	3
	Hypertension	1	4	36	11
		2	12	36	33
		3	10	36	28

Leiomyosarcoma

Table 18: Number and percentage of patients experiencing an adverse event reported by the maximum grade experienced and split by CTCAE categorisations and toxicity in the Leiomyosarcoma subgroup

Category	Toxicity	Grade	Affected	Exposed	Percentage Affected
Gastrointestinal disorders	Anemia	1	1	35	3
	Cardiac disorders	1	1	35	3
	Ear and labyrinth disorders	1	2	35	6
	Endocrine disorders	2	1	35	3
	Abdominal pain	1	9	35	26
		2	2	35	6
	Bloating	2	1	35	3
	Constipation	1	10	35	29
		2	5	35	14
	Diarrhea	1	9	35	26
		2	6	35	17
		3	2	35	6
	Dry mouth	1	4	35	11
		2	1	35	3
	Dyspepsia	1	6	35	17
		2	1	35	3
	Flatulence	2	2	35	6
	Gastroesophageal reflux disease	1	2	35	6
	Glossitis	1	1	35	3
	Mucositis oral	1	12	35	34
		2	7	35	20
	Nausea	1	12	35	34
		2	8	35	23
	Oral hemorrhage	1	1	35	3
	Oral pain	1	2	35	6
	Oral sensitivity	2	2	35	6
	Stomach pain	1	2	35	6
		2	1	35	3
	Toothache	1	2	35	6
	Vomiting	1	5	35	14
		2	5	35	14
General disorders and administration site conditions	Chills	2	1	35	3
		1	3	35	9
		2	1	35	3
	Fatigue	1	11	35	31
		2	10	35	29
		3	6	35	17
	Fever	1	2	35	6
		3	1	35	3
	Malaise	1	1	35	3
	Non-cardiac chest pain	1	2	35	6
	Pain	1	9	35	26
		2	3	35	9

Immune system disorders	Serum sickness	3	1	35	3
		1	1	35	3

Category	Toxicity	Grade	Affected	Exposed	Percentage Affected
Infections and infestations	Bronchial infection	1	1	35	3
	Mucosal infection	1	2	35	6
	Skin infection	2	1	35	3
	Tooth infection	2	1	35	3
	Upper respiratory infection	2	1	35	3
		3	1	35	3
	Urinary tract infection	1	2	35	6
		2	4	35	11
	Viral cold	1	2	35	6
	Bruising	1	1	35	3
Injury, poisoning and procedural complications	Alanine aminotransferase increased	1	1	35	3
	Alkaline phosphatase increased	1	1	35	3
	Aspartate aminotransferase increased	1	1	35	3
	GGT increased	1	1	35	3
	Weight loss	1	7	35	20
		2	5	35	14
		3	3	35	9
Metabolism and nutrition disorders	Anorexia	1	8	35	23
		2	10	35	29
		3	2	35	6
	Hypercalcemia	4	1	35	3
	Hyperglycemia	2	1	35	3
		3	1	35	3
	Hypophosphatemia	3	1	35	3
Musculoskeletal and connective tissue disorders	Arthralgia	1	11	35	31
		2	2	35	6
		3	2	35	6
	Back pain	1	4	35	11
	Bone pain	1	2	35	6
	Chest wall pain	1	2	35	6
	Cramp	1	2	35	6
	Flank pain	1	1	35	3
	Joint stiffness	1	1	35	3
	Myalgia	1	3	35	9
		3	1	35	3
	Pain in extremity	1	5	35	14

Category	Toxicity	Grade	Affected	Exposed	Percentage Affected
Nervous system disorders	Amnesia	1	1	35	3
	Dizziness	1	2	35	6
	Dysgeusia	1	3	35	9
	Dysphasia	1	1	35	3
	Facial nerve disorder	2	1	35	3
	Headache	1	10	35	29
		2	2	35	6
		3	2	35	6
	Lethargy	2	1	35	3
	Paresthesia	1	3	35	9
	Peripheral motor neuropathy	1	1	35	3
	Peripheral neuropathy	1	1	35	3
	Peripheral sensory neuropathy	1	2	35	6
		2	1	35	3
	Tremor	1	1	35	3
	Depression	1	1	35	3
		3	1	35	3
Psychiatric disorders	Insomnia	1	2	35	6
	Mood alteration	3	1	35	3
Renal and urinary disorders	Burning on passing urine	1	1	35	3
	Dysuria	1	1	35	3
	Hematuria	1	1	35	3
	Proteinuria	1	11	35	31
		2	5	35	14
Respiratory, thoracic and mediastinal disorders	Suprapubic discomfort	1	1	35	3
	Cough	1	13	35	37
		2	2	35	6
	Dyspnea	1	13	35	37
		2	2	35	6
		3	1	35	3
	Epistaxis	1	1	35	3
		2	1	35	3
	Hoarseness	1	1	35	3
	Laryngeal hemorrhage	2	1	35	3
	Sore throat	1	1	35	3
		3	1	35	3
	Voice alteration	1	9	35	26
		2	2	35	6

Category	Toxicity	Grade	Affected	Exposed	Percentage Affected
Skin and subcutaneous tissue disorders	Alopecia	1	2	35	6
		2	1	35	3
	Brittle nails	1	1	35	3
	Dermatitis	1	1	35	3
	Dry skin	1	5	35	14
	Hair depigmentation	1	1	35	3
	Hyperhidrosis	2	1	35	3
	Nail discoloration	1	1	35	3
	Nail loss	2	1	35	3
	Palmar-plantar erythrodysesthesia syndrome	1	7	35	20
		2	1	35	3
	Pruritus	1	1	35	3
	Scalp pain	1	1	35	3
	Flushing	1	1	35	3
	Hot flashes	1	1	35	3
Vascular disorders	Hypertension	1	8	35	23
		2	14	35	40
		3	6	35	17
	Hypotension	1	1	35	3

Synovial Sarcoma

Table 19: Number and percentage of patients experiencing an adverse event reported by the maximum grade experienced and split by CTCAE categorisations and toxicity in the Synovial subgroup

Category	Toxicity	Grade	Affected	Exposed	Percentage Affected
Blood and lymphatic system disorders	Anemia	1	2	34	6
	Cardiac disorders	1	1	34	3
	Endocrine disorders	1	1	34	3
	Hyperthyroidism	1	1	34	3
	Hypoparathyroidism	2	1	34	3
	Hypothyroidism	1	1	34	3
Eye disorders		2	5	34	15
	Dry eye	1	1	34	3
	Retinal vascular disorder	3	1	34	3
Gastrointestinal disorders	Abdominal pain	1	5	34	15
		2	3	34	9
	Bloating	1	1	34	3
	Constipation	1	9	34	26
		2	1	34	3
	Dental caries	1	1	34	3
		2	1	34	3
	Diarrhea	1	11	34	32
		2	5	34	15
		3	1	34	3
	Dry mouth	1	3	34	9
	Dry throat	1	1	34	3
	Dyspepsia	1	3	34	9
	Flatulence	1	2	34	6
	Glossitis	2	1	34	3
	Lower gastrointestinal hemorrhage	3	1	34	3
	Mucositis oral	1	7	34	21
		2	6	34	18
	Nausea	1	13	34	38
		2	2	34	6
	Oral pain	1	1	34	3
		2	1	34	3
	Vomiting	1	6	34	18
		2	1	34	3
General disorders and administration site conditions	Chills	1	1	34	3
	Edema limbs	2	1	34	3
	Fatigue	1	13	34	38
		2	13	34	38
		3	2	34	6
	Fever	1	1	34	3
		2	1	34	3
		3	1	34	3
	Flu like symptoms	1	2	34	6
	Malaise	1	1	34	3
	Non-cardiac chest pain	1	5	34	15

Pain

2	2	34	6
3	1	34	3
1	7	34	21
2	4	34	12
3	1	34	3

Category	Toxicity	Grade	Affected	Exposed	Percentage Affected
Infections and infestations	Bronchial infection	2	2	34	6
	Lip infection	1	1	34	3
	Lung infection	1	1	34	3
		2	1	34	3
		4	1	34	3
	Otitis externa	2	1	34	3
	Otitis media	2	1	34	3
	Penile infection	2	1	34	3
	Pharyngitis	2	1	34	3
	Scrotal infection	2	1	34	3
	Tooth infection	1	1	34	3
	Upper respiratory infection	1	2	34	6
	Urinary tract infection	1	1	34	3
		2	2	34	6
	Viral cold	1	1	34	3
	Wound infection	2	1	34	3
Injury, poisoning and procedural complications	Fall	2	1	34	3
	Fracture	2	1	34	3
Investigations	Alanine aminotransferase increased	1	2	34	6
	GGT increased	3	2	34	6
	Neutrophil count decreased	1	1	34	3
	Platelet count decreased	1	1	34	3
	Weight loss	1	10	34	29
		2	2	34	6
	White blood cell decreased	1	1	34	3
Metabolism and nutrition disorders	Anorexia	1	13	34	38
		2	2	34	6
	Hyperkalemia	1	1	34	3
	Hypocalcemia	3	1	34	3
	Hyponatremia	1	1	34	3
Musculoskeletal and connective tissue disorders	Arthralgia	1	7	34	21
		2	2	34	6
	Back pain	1	1	34	3
	Bone pain	2	1	34	3
	Muscle weakness right-sided	1	1	34	3
	Myalgia	2	1	34	3
	Neck pain	1	1	34	3
		2	1	34	3
	Pain in extremity	1	2	34	6
		2	2	34	6
		3	1	34	3
		1	1	34	3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Gallbladder polyps	1	1	34	3

Category	Toxicity	Grade	Affected	Exposed	Percentage Affected
Nervous system disorders	Cognitive disturbance	2	1	34	3
	Dysesthesia	1	1	34	3
	Dysgeusia	1	1	34	3
	Headache	1	10	34	29
		2	2	34	6
	Memory impairment	2	1	34	3
	Paresthesia	1	2	34	6
	Peripheral motor neuropathy	3	1	34	3
	Peripheral sensory neuropathy	1	1	34	3
		3	1	34	3
Psychiatric disorders	Spinal cord compression	3	1	34	3
	Confusion	2	1	34	3
	Depression	1	1	34	3
	Insomnia	1	1	34	3
Renal and urinary disorders	Proteinuria	1	3	34	9
		2	4	34	12
Reproductive system and breast disorders	Menorrhagia	1	1	34	3
	Pelvic pain	2	2	34	6
	Vaginal pain	2	1	34	3
Respiratory, thoracic and mediastinal disorders	Bronchopulmonary hemorrhage	1	1	34	3
		3	1	34	3
	Cough	1	11	34	32
		2	5	34	15
	Dyspnea	1	12	34	35
		2	6	34	18
		3	2	34	6
		4	1	34	3
	Epistaxis	1	2	34	6
	Hoarseness	1	1	34	3
	Nasal congestion	1	1	34	3
	Pleural effusion	3	1	34	3
	Pleural hemorrhage	2	1	34	3
	Pleuritic pain	1	1	34	3
	Pneumothorax	2	1	34	3
		3	2	34	6
	Productive cough	1	1	34	3
	Sore throat	1	2	34	6
		2	1	34	3
	Voice alteration	1	18	34	53
		2	1	34	3

Category	Toxicity	Grade	Affected	Exposed	Percentage Affected
Skin and subcutaneous tissue disorders	Alopecia	1	1	34	3
	Dry skin	1	3	34	9
	Hyperhidrosis	1	2	34	6
	Pain of skin	2	1	34	3
	Palmar-plantar erythrodysesthesia syndrome	1	5	34	15
		2	3	34	9
	Pruritus	2	1	34	3
	Rash acneiform	1	1	34	3
		2	1	34	3
	Skin reaction	1	1	34	3
Vascular disorders	Hot flashes	1	2	34	6
	Hypertension	1	6	34	18
		2	14	34	41
		3	1	34	3
	Hypotension	1	1	34	3
	Thromboembolic event	2	2	34	6

Other Sarcoma

Table 20: Number and percentage of patients experiencing an adverse event reported by the maximum grade experienced and split by CTCAE categorisations and toxicity in the Other subgroup

Category	Toxicity	Grade	Affected	Exposed	Percentage Affected
Blood and lymphatic system disorders	Anemia	2	1	31	3
		3	1	31	3
Ear and labyrinth disorders	Blocked ears	1	3	31	10
Endocrine disorders	Hyperthyroidism	2	1	31	3
	Hypothyroidism	1	1	31	3
Eye disorders	Dry eye	1	1	31	3
	Glaucoma	1	2	31	6
Gastrointestinal disorders	Abdominal pain	1	5	31	16
		2	3	31	10
		3	2	31	6
	Bloating	2	1	31	3
	Change in bowel habits	1	1	31	3
	Colonic fistula	3	1	31	3
	Constipation	1	11	31	35
		2	2	31	6
		3	3	31	10
	Diarrhea	1	7	31	23
		2	2	31	6
		3	3	31	10
	Dry mouth	1	3	31	10
	Dyspepsia	1	4	31	13
	Gastritis	2	1	31	3
	Mucositis oral	1	11	31	35
		2	2	31	6
		3	2	31	6
	Nausea	1	13	31	42
		2	3	31	10
	Oral pain	1	3	31	10
		2	1	31	3
	Oral sensitivity	1	1	31	3
	Rectal hemorrhage	1	1	31	3
	Vomiting	1	4	31	13
		2	2	31	6
		3	1	31	3
General disorders and administration site conditions	Edema limbs	1	1	31	3
		2	9	31	29
	Fatigue	2	13	31	42
		3	6	31	19
	Non-cardiac chest pain	1	2	31	6
		2	2	31	6
	Pain	1	5	31	16
		2	11	31	35

Category	Toxicity	Grade	Affected	Exposed	Percentage Affected
Hepatobiliary disorders	Hepatic pain	1	2	31	6
	Bronchial infection	2	1	31	3
Infections and infestations	Lip infection	1	1	31	3
	Lung infection	2	1	31	3
	Mucosal infection	2	1	31	3
	Peripheral nerve infection	2	1	31	3
	Urinary tract infection	2	3	31	10
	Viral cold	1	1	31	3
	Viral infection	1	1	31	3
	Alanine aminotransferase increased	2	1	31	3
Investigations	Alkaline phosphatase increased	1	1	31	3
	Aspartate aminotransferase increased	1	1	31	3
	Blood bilirubin increased	1	1	31	3
	GGT increased	2	1	31	3
	Lactate dehydrogenase abnormal	1	1	31	3
	Platelet count decreased	2	1	31	3
	Weight loss	1	4	31	13
		2	4	31	13
Metabolism and nutrition disorders	Anorexia	1	11	31	35
		2	5	31	16
	Dehydration	1	1	31	3
	Hypercalcemia	1	1	31	3
	Hypocalcemia	1	1	31	3
Musculoskeletal and connective tissue disorders	Arthralgia	1	3	31	10
		2	2	31	6
	Arthritis	1	1	31	3
	Back pain	1	2	31	6
		2	1	31	3
		3	1	31	3
	Bone pain	1	1	31	3
		2	2	31	6
	Chest wall pain	1	1	31	3
	Cramp	1	2	31	6
	Flank pain	1	1	31	3
	Pain in extremity	1	1	31	3
		2	2	31	6
	Stiffness of calves	1	1	31	3

Category	Toxicity	Grade	Affected	Exposed	Percentage Affected
Nervous system disorders	Ataxia	1	1	31	3
	Dizziness	1	3	31	10
	Dysgeusia	1	3	31	10
	Headache	1	10	31	32
		2	1	31	3
	Migraine	2	1	31	3
	Neuralgia	1	1	31	3
		2	1	31	3
	Paresthesia	1	2	31	6
		2	1	31	3
	Peripheral sensory neuropathy	1	1	31	3
	Spasticity	1	1	31	3
	Tremor	1	1	31	3
Psychiatric disorders	Anxiety	1	2	31	6
	Confusion	1	1	31	3
	Depression	1	2	31	6
	Insomnia	1	1	31	3
Renal and urinary disorders	Proteinuria	1	4	31	13
		2	2	31	6
	Urinary frequency	1	2	31	6
	Urinary urgency	1	1	31	3
Respiratory, thoracic and mediastinal disorders	Cough	1	13	31	42
		2	1	31	3
	Dyspnea	1	11	31	35
		2	3	31	10
	Laryngeal hemorrhage	1	2	31	6
	Nasal congestion	1	1	31	3
	Pleural hemorrhage	3	1	31	3
	Pneumothorax	3	1	31	3
	Sore throat	2	1	31	3
	Voice alteration	1	7	31	23
		2	1	31	3
	Wheezing	1	1	31	3

Category	Toxicity	Grade	Affected	Exposed	Percentage Affected
Skin and subcutaneous tissue disorders	Dry skin	1	3	31	10
	Erythema multiforme	1	1	31	3
	Hyperhidrosis	1	1	31	3
	Onychocryptosis	1	1	31	3
	Palmar-plantar erythrodysesthesia syndrome	1	5	31	16
		2	4	31	13
	Pruritus	2	1	31	3
	Rash acneiform	1	3	31	10
		2	1	31	3
	Hypertension	1	4	31	13
Vascular disorders		2	9	31	29
		3	6	31	19
	Leaking intra-tumoural renal artery	3	1	31	3
	Phlebitis	2	1	31	3
	Thromboembolic event	3	2	31	6

Serious Adverse Events

Table 21: Serious Adverse Events in the Angiosarcoma subgroup

Category	Toxicity	Affected	Exposed	Occurrences	Fatal	Related	Related & Fatal	Percentage Affected
Cardiac disorders	Sinus bradycardia	1	36	1	0	0	0	2.8
Gastrointestinal disorders	Abdominal pain	1	36	2	0	2	0	2.8
	Duodenal perforation	1	36	1	0	1	0	2.8
	Stomach pain	1	36	1	0	0	0	2.8
	Fatigue	1	36	1	0	1	0	2.8
General disorders and administration site conditions	Fever	2	36	2	0	0	0	5.6
Investigations	Platelet count decreased	1	36	1	0	0	0	2.8
Musculoskeletal and connective tissue disorders	Chest wall pain	1	36	1	0	0	0	2.8
	Flank pain	1	36	1	0	1	0	2.8
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Disease Progression	1	36	1	1	1	1	2.8
Psychiatric disorders	Confusion	1	36	1	1	0	0	2.8
Respiratory, thoracic and mediastinal disorders	Dyspnea	1	36	1	0	0	0	2.8
	Pleural effusion	2	36	2	0	0	0	5.6
	Pneumothorax	1	36	2	0	2	0	2.8
Skin and subcutaneous tissue disorders	Bleeding	1	36	1	0	1	0	2.8
Vascular disorders	Hypertension	1	36	1	0	1	0	2.8

Leiomyosarcoma

Table 22: Serious Adverse Events in the Leiomyosarcoma subgroup

Category	Toxicity	Affected	Exposed	Occurrences	Fatal	Related	Related & Fatal	Percentage Affected
Cardiac disorders	Atrial fibrillation	1	35	1	0	1	0	2.9
Gastrointestinal disorders	Abdominal pain	1	35	1	0	0	0	2.9
	Colonic obstruction	1	35	1	1	0	0	2.9
	Gastric hemorrhage	1	35	1	1	1	1	2.9
	Fatigue	1	35	1	0	0	0	2.9
General disorders and administration site conditions	Pain	1	35	1	0	0	0	2.9
Metabolism and nutrition disorders	Dehydration	1	35	1	0	1	0	2.9
	Hypercalcemia	1	35	1	0	0	0	2.9
Musculoskeletal and connective tissue disorders	Bone pain	1	35	1	0	0	0	2.9
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Disease Progression	1	35	1	1	1	1	2.9
Respiratory, thoracic and mediastinal disorders	Dyspnea	1	35	1	1	0	0	2.9
Surgical and medical procedures	Haemoptysis	1	35	1	0	1	0	2.9
	Pump Re-Dosing	1	35	1	0	0	0	2.9
	Thoracotomy/Pneumonectomy	1	35	1	0	0	0	2.9

Synovial Sarcoma

Table 23: Serious Adverse Events in the Synovial Sarcoma subgroup

Category	Toxicity	Affected	Exposed	Occurrences	Fatal	Related	Related & Fatal	Percentage Affected
Eye disorders	Retinal vascular disorder	1	34	1	0	1	0	2.9
Gastrointestinal disorders	Lower gastrointestinal hemorrhage	1	34	1	0	1	0	2.9
General disorders and administration site conditions	Fatigue	1	34	1	0	0	0	2.9
Infections and infestations	Fever	1	34	1	0	0	0	2.9
	Pain	2	34	3	0	0	0	5.9
	Anorectal infection	1	34	1	0	1	0	2.9
	Bronchial infection	1	34	1	0	1	0	2.9
	Herpes Zoster	1	34	1	0	1	0	2.9
	Lung infection	1	34	1	0	1	0	2.9
	Hypocalcemia	1	34	1	0	1	0	2.9
Metabolism and nutrition disorders	Hypocalcemia	1	34	1	0	1	0	2.9
Musculoskeletal and connective tissue disorders	Muscle weakness lower limb	1	34	1	0	0	0	2.9

Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cerebral Metastasis With Intracranial Hemorrhage	1	34	1	0	1	0	2.9
Respiratory, thoracic and mediastinal disorders	Bronchopulmonary hemorrhage	1	34	1	0	0	0	2.9
	Chest Pain	1	34	1	0	0	0	2.9
	Dyspnea	3	34	3	0	2	0	8.8
	Lrti	1	34	1	0	0	0	2.9
	Pleural effusion	2	34	2	1	0	0	5.9
	Pneumothorax	3	34	3	0	3	0	8.8
	Respiratory failure	1	34	1	1	1	1	2.9

Other Sarcoma

Table 24: Serious Adverse Events in the Other subgroup

Category	Toxicity	Affected	Exposed	Occurrences	Fatal	Related	Related & Fatal	Percentage Affected
Gastrointestinal disorders	Abdominal pain	1	31	1	0	0	0	3.2
	Ascites	1	31	1	0	0	0	3.2
	Diarrhea	1	31	1	0	0	0	3.2
	Rectal hemorrhage	1	31	1	0	0	0	3.2
	Vomiting	1	31	1	0	0	0	3.2
General disorders and administration site conditions	Pain	1	31	1	0	1	0	3.2
Infections and infestations	Wound infection	1	31	1	0	1	0	3.2
Injury, poisoning and procedural complications	Wound complication	1	31	1	0	0	0	3.2
Musculoskeletal and connective tissue disorders	Chest wall pain	1	31	1	0	0	0	3.2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Disease Progression	1	31	1	1	0	0	3.2
Renal and urinary disorders	Dysuria	1	31	1	0	0	0	3.2
	Renal hemorrhage	1	31	1	0	1	0	3.2
Respiratory, thoracic and mediastinal disorders	Haemoptysis	1	31	1	1	1	1	3.2
	Pneumothorax	1	31	1	0	1	0	3.2